Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works

A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids.

Wessel, D., & Flügge, U. (1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90782-6 · Cited by 3,997 · see citing works

Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17

Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498 · see citing works

Neurodegenerative Tauopathies

Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · see citing works

Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function

SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014 · see citing works

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

Cross Talk Between O-GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription, and Chronic Disease

Hart, G. W., Slawson, C., Ramirez-Correa, G., & Lagerlof, O. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060608-102511 · Cited by 1,317 · see citing works

Tau pathology and neurodegeneration

Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133 · see citing works

Biochemistry and Cell Biology of Tau Protein in Neurofibrillary DegenerationPreprint

Mandelkow, E., & Mandelkow, E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006247 · Cited by 839 · see citing works

A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo

Yuzwa, S. A., Macauley, M. S., Heinonen, J. E., Shan, X., Dennis, R. J., He, Y., Whitworth, G. E., Stubbs, K. A., McEachern, E. J., Davies, G. J., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.96 · Cited by 717 · see citing works

Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L)

Ramsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3279-05.2005 · Cited by 702 · see citing works

Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation

Yuzwa, S. A., Shan, X., Macauley, M. S., Clark, T., Skorobogatko, Y., Vosseller, K., & Vocadlo, D. J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.797 · Cited by 611 · see citing works

Monoclonal antibodies identify a group of nuclear pore complex glycoproteins.

Snow, C. M., Senior, A., & Gerace, L. (1987) · The Journal of Cell Biology · doi:10.1083/jcb.104.5.1143 · Cited by 542 · see citing works

Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice

Morris, M., Knudsen, G. M., Maeda, S., Trinidad, J. C., Ioanoviciu, A., Burlingame, A. L., & Mucke, L. (2015) · Nature Neuroscience · doi:10.1038/nn.4067 · Cited by 472 · see citing works

Mutations causing neurodegenerative tauopathies

Goedert, M., & Jakes, R. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.007 · Cited by 438 · see citing works

The Microtubule-associated Protein Tau Is Extensively Modified with O-linked N-acetylglucosamine

Arnold, C. S., Johnson, G. W., Cole, R. N., Dong, D. L.-Y., Lee, M., & Hart, G. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28741 · Cited by 361 · see citing works

O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease

Marotta, N. P., Lin, Y., Lewis, Y. E., Ambroso, M. R., Zaro, B. W., Roth, M. T., Arnold, D. B., Langen, R., & Pratt, M. R. (2015) · Nature Chemistry · doi:10.1038/nchem.2361 · Cited by 303 · see citing works

The Emerging Link between O-GlcNAc and Alzheimer Disease

Zhu, Y., Shan, X., Yuzwa, S. A., & Vocadlo, D. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.601351 · Cited by 267 · see citing works

O‐GlcNAcase is essential for embryonic development and maintenance of genomic stability

Yang, Y. R., Song, M., Lee, H., Jeon, Y., Choi, E., Jang, H., Moon, H. Y., Byun, H., Kim, E., Kim, D. H., et al. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00801.x · Cited by 244 · see citing works

Identification of protein O-GlcNAcylation sites using electron transfer dissociation mass spectrometry on native peptides

Chalkley, R. J., Thalhammer, A., Schoepfer, R., & Burlingame, A. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900288106 · Cited by 237 · see citing works

Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice

Yuzwa, S. A., Shan, X., Jones, B. A., Zhao, G., Woodward, M. L., Li, X., Zhu, Y., McEachern, E. J., Silverman, M. A., Watson, N. V., et al. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-42 · Cited by 151 · see citing works

O-GlcNAc Modification of tau Directly Inhibits Its Aggregation without Perturbing the Conformational Properties of tau Monomers

Yuzwa, S. A., Cheung, A. H., Okon, M., McIntosh, L. P., & Vocadlo, D. J. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.01.004 · Cited by 143 · see citing works

Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody

Yuzwa, S. A., Yadav, A. K., Skorobogatko, Y., Clark, T., Vosseller, K., & Vocadlo, D. J. (2011) · Amino Acids · doi:10.1007/s00726-010-0705-1 · Cited by 130 · see citing works

Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy

Graham, D. L., Gray, A. J., Joyce, J. A., Yu, D., O’Moore, J., Carlson, G. A., Shearman, M. S., Dellovade, T., & Hering, H. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.025 · Cited by 129 · see citing works

O-GlcNAcylation Prevents Aggregation of the Polycomb Group Repressor Polyhomeotic

Gambetta, M. C., & Müller, J. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.10.020 · Cited by 126 · see citing works

Differential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation

Yu, Y., Zhang, L., Li, X., Run, X., Liang, Z., Li, Y., Liu, Y., Lee, M. H., Grundke, I., Iqbal, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035277 · Cited by 113 · see citing works

Reversible gene knockdown in mice using a tight, inducible shRNA expression system

Seibler, J., Kleinridders, A., Birgit, K.-L., Sandra, N., Brüning, J. C., & Schwenk, F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm122 · Cited by 113 · see citing works

Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

Khanna, M. R., Kovalevich, J., Lee, V. M. ‐., Trojanowski, J. Q., & Brunden, K. R. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.006 · Cited by 112 · see citing works

Single copy shRNA configuration for ubiquitous gene knockdown in mice

Seibler, J. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni065 · Cited by 109 · see citing works

Endoglycosidase and Glycoamidase Release of N‐Linked Glycans

Freeze, H. H., & Kranz, C. (2010) · Current Protocols in Protein Science · doi:10.1002/0471140864.ps1204s62 · Cited by 105 · see citing works

Increasing Brain Protein O-GlcNAc-ylation Mitigates Breathing Defects and Mortality of Tau.P301L Mice

Borghgraef, P., Menuet, C., Theunis, C., Louis, J. V., Devijver, H., Maurin, H., Smet‐Nocca, C., Lippens, G. M., Hilaire, G., Gijsen, H. J. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084442 · Cited by 99 · see citing works

Tau Transgenic Mice as Models for Cerebrospinal Fluid Tau Biomarkers

Barten, D. M., Cadelina, G. W., Hoque, N., DeCarr, L. B., Guss, V. L., Yang, L., Sankaranarayanan, S., Wes, P. D., Flynn, M. E., Meredith, J. E., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110161 · Cited by 87 · see citing works

Endoglycosidase and Glycoamidase Release of N‐Linked Glycans

Freeze, H. H., & Kranz, C. (2010) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb1713as89 · Cited by 66 · see citing works

Analyzing Binding Data

Motulsky, H. J., & Neubig, R. R. (2010) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0705s52 · Cited by 63 · see citing works

Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology

Song, L., Lu, S. X., Ouyang, X., Melchor, J. P., Lee, J., Terracina, G., Wang, X., Hyde, L. A., Hess, J. F., Parker, E. M., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0011-1 · Cited by 51 · see citing works

The wheat germ agglutinin‐fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: Implications for disease pathogenesis and progression

Domenico, F. D., Owen, J. B., Rukhsana Sultana, A., Robinson, R. A. S., Marzia Perluigi, A., Cini, C., Cai, J., Pierce, W. M. J., & Butterfield, D. A. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22528 · Cited by 38 · see citing works

O2‐13‐04: Early Clinical Results and Preclinical Validation of the O‐Glcnacase (OGA) Inhibitor Mk‐8719 as a Novel Therapeutic for the Treatment of Tauopathies

Smith, S. M., Struyk, A. F., Jonathan, D., Declercq, R., Marcus, J., Toolan, D. M., Wang, X., Schachter, J. B., Cosden, M. L., Pearson, M. S., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.469 · Cited by 24 · see citing works

Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation

Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516 · see citing works

Nutrient regulation of signaling and transcription

Hart, G. W. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.aw119.003226 · Cited by 346 · see citing works

Tau Proteins and Tauopathies in Alzheimer’s Disease

Chong, F. P., Ng, K. Y., Koh, R. Y., & Chye, S. M. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0574-1 · Cited by 248 · see citing works

The human O-GlcNAcome database and meta-analysis

Wulff‐Fuentes, E., Berendt, R., Massman, L., Danner, L., Malard, F., Vora, J. K., Kahsay, R., & Stichelen, S. O.-V. (2021) · Scientific Data · doi:10.1038/s41597-021-00810-4 · Cited by 247 · see citing works

Four-repeat tauopathies

Rösler, T. W., Marvian, A. T., Brendel, M., Nykänen, N.-P., Höllerhage, M., Schwarz, S. C., Hopfner, F., Koeglsperger, T., Respondek, G., Schweyer, K., et al. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101644 · Cited by 219 · see citing works

The Interplay Among Oxidative Stress, Brain Insulin Resistance and AMPK Dysfunction Contribute to Neurodegeneration in Type 2 Diabetes and Alzheimer Disease

Barone, E., Domenico, F. D., Perluigi, M., & Butterfield, D. (2021) · Free Radical Biology & Medicine · doi:10.1016/j.freeradbiomed.2021.09.006 · Cited by 155 · see citing works

Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies

Limorenko, G., & Lashuel, H. A. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00127b · Cited by 162 · see citing works

Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies

Selnick, H. G., Hess, J. F., Tang, C., Liu, K., Schachter, J. B., Ballard, J. E., Marcus, J., Klein, D. J., Wang, X., Pearson, M. S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01090 · Cited by 144 · see citing works

<i>O</i> -GlcNAcylation ameliorates the pathological manifestations of Alzheimer’s disease by inhibiting necroptosis

Park, J., Ha, H.-J., Chung, E. S., Baek, S. H., Cho, Y., Kim, H. K., Han, J., Sul, J. H., Lee, J., Kim, E., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd3207 · Cited by 139 · see citing works

Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122 · see citing works

Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention

Peng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants &amp; Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110 · see citing works

Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer’s disease –conformist, nonconformist, and realistic prospects for AD pathogenesis

Li, H., Liu, C.-C., Zheng, H., & Huang, T. Y. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0139-3 · Cited by 103 · see citing works

Targeting O-GlcNAcylation to develop novel therapeutics

Zhu, Y., & Hart, G. W. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100885 · Cited by 92 · see citing works

Small molecule therapeutics for tauopathy in Alzheimer’s disease: Walking on the path of most resistance

Wang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92 · see citing works

Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease

Austad, S. N., Ballinger, S. W., Buford, T. W., Carter, C. S., Smith, D. L., Darley-Usmar, V. M., & Zhang, J. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.014 · Cited by 94 · see citing works

O-GlcNAc modification of small heat shock proteins enhances their anti-amyloid chaperone activity

Balana, A. T., Levine, P. M., Craven, T. W., Mukherjee, S., Pedowitz, N. J., Moon, S. P., Takahashi, T. T., Becker, C. F. W., Baker, D. A., & Pratt, M. R. (2021) · Nature Chemistry · doi:10.1038/s41557-021-00648-8 · Cited by 90 · see citing works

Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies

Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 87 · see citing works

O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease

Ryan, P., Xu, M., Davey, A. K., Danon, J. J., Mellick, G. D., Kassiou, M., & Rudrawar, S. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00143 · Cited by 84 · see citing works

O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies

Permanne, B., Sand, A., Ousson, S., Nény, M., Hantson, J., Schubert, R., Wiessner, C., Quattropani, A., & Beher, D. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00057 · Cited by 82 · see citing works

Nutrient‐driven O‐Glc NA c in proteostasis and neurodegeneration

Akan, I., Stichelen, S. O.-V., Bond, M. R., & Hanover, J. A. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14242 · Cited by 82 · see citing works

MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy

Wang, X., Li, W., Marcus, J., Pearson, M. S., Song, L., Smith, K. D. B., Terracina, G., Lee, J. A., Hong, K.-L. K., Lu, S. X., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.266122 · Cited by 83 · see citing works

O-GlcNAcylation as a Therapeutic Target for Alzheimer’s Disease

Park, J., Lai, M. K. P., Arumugam, T. V., & Jo, D. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08584-0 · Cited by 75 · see citing works

A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies

Imbimbo, B. P., Ippati, S., Watling, M., & Balducci, C. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12453 · Cited by 72 · see citing works

Loss of GFAT-1 feedback regulation activates the hexosamine pathway that modulates protein homeostasis

Ruegenberg, S., Horn, M., Pichlo, C., Allmeroth, K., Baumann, U., & Denzel, M. S. (2020) · Nature Communications · doi:10.1038/s41467-020-14524-5 · Cited by 71 · see citing works

Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies

Pinho, T. S., Correia, S. C., Perry, G., Ambrósio, A. F., & Moreira, P. I. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.037 · Cited by 70 · see citing works

REM Sleep Deprivation Impairs Learning and Memory by Decreasing Brain O-GlcNAc Cycling in Mouse

Kim, S.-M., Zhang, S., Park, J., Sung, H. J., Tran, T.-D. T., Chung, C., & Han, I. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01094-7 · Cited by 69 · see citing works

Pharmacological Inhibition of O-GlcNAcase Enhances Autophagy in Brain through an mTOR-Independent Pathway

Zhu, Y., Shan, X., Safarpour, F., Go, N. E., Li, N., Shan, A., Huang, M. C., Deen, M. C., Holicek, V., Ashmus, R. A., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00015 · Cited by 66 · see citing works

O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature

Bartolomé-Nebreda, J. M., Trabanco, A. A., Velter, A. I., & Buijnsters, P. J. J. A. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1947242 · Cited by 62 · see citing works

Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities

Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61 · see citing works

Phosphorylation and O-GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates

Cantrelle, F., Loyens, A., Trivelli, X., Reimann, O., Despres, C., Gandhi, N. S., Hackenberger, C. P. R., Landrieu, I., & Smet‐Nocca, C. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.661368 · Cited by 62 · see citing works

Integration of O-GlcNAc into Stress Response Pathways

Fahie, K., Papanicolaou, K. N., & Zachara, N. E. (2022) · Cells · doi:10.3390/cells11213509 · Cited by 62 · see citing works

SUMOylation and the HSF1-Regulated Chaperone Network Converge to Promote Proteostasis in Response to Heat Shock

Liebelt, F., Sebastian, R. M., Moore, C. L., Mulder, M. P. C., Ovaa, H., Shoulders, M. D., & Vertegaal, A. C. O. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.027 · Cited by 59 · see citing works

Systems biology identifies preserved integrity but impaired metabolism of mitochondria due to a glycolytic defect in Alzheimer's disease neurons

Theurey, P., Connolly, N. M. C., Fortunati, I., Basso, E., Lauwen, S., Ferrante, C., Pinho, C. M., Joselin, A. P., Gioran, A., Bano, D., et al. (2019) · Aging Cell · doi:10.1111/acel.12924 · Cited by 57 · see citing works

Opportunities for Therapeutic Modulation of O-GlcNAc

Cheng, S. S., Mody, A. C., & Woo, C. M. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00417 · Cited by 61 · see citing works

Understanding and exploiting the roles of O-GlcNAc in neurodegenerative diseases

Pratt, M. R., & Vocadlo, D. J. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105411 · Cited by 54 · see citing works

Pharmacological inhibition and knockdown of O‐GlcNAcase reduces cellular internalization of α‐synuclein preformed fibrils

Tavassoly, O., Yue, J., & Vocadlo, D. J. (2020) · FEBS Journal · doi:10.1111/febs.15349 · Cited by 52 · see citing works

Direct Crosstalk Between O-GlcNAcylation and Phosphorylation of Tau Protein Investigated by NMR Spectroscopy

Bourré, G., Cantrelle, F., Kamah, A., Chambraud, B., Landrieu, I., & Smet‐Nocca, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00595 · Cited by 51 · see citing works

O-GlcNAc homeostasis contributes to cell fate decisions during hematopoiesis

Zhang, Z., Parker, M. P., Graw, S., Novikova, L., Fedosyuk, H., Fontes, J. D., Koestler, D. C., Peterson, K. R., & Slawson, C. M. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005993 · Cited by 49 · see citing works

Loss of O-GlcNAcase catalytic activity leads to defects in mouse embryogenesis

Muha, V., Authier, F., Szoke-Kovacs, Z., Johnson, S., Gallagher, J. R., McNeilly, A. D., McCrimmon, R. J., Teboul, L., & van Aalten, D. M. F. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100439 · Cited by 47 · see citing works

Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders

Balana, A. T., & Pratt, M. R. (2021) · Biochemical Journal · doi:10.1042/bcj20200609 · Cited by 45 · see citing works

Monitoring and modulating O-GlcNAcylation: assays and inhibitors of O-GlcNAc processing enzymes

Alteen, M. G., Tan, H. Y., & Vocadlo, D. J. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.12.008 · Cited by 45 · see citing works

Chronic hyperglycemia induces tau hyperphosphorylation by downregulating OGT-involved O-GlcNAcylation in vivo and in vitro

Huang, R., Tian, S., Zhang, H., Zhu, W., & Wang, S. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.01.006 · Cited by 44 · see citing works

Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy?

Brembati, V., Faustini, G., Longhena, F., & Bellucci, A. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1197853 · Cited by 42 · see citing works

Evaluation of a PET Radioligand to Image O-GlcNAcase in Brain and Periphery of Rhesus Monkey and Knock-Out Mouse

Paul, S., Haskali, M. B., Liow, J., Zoghbi, S. S., Barth, V., Comly, M., Bond, M. R., Morse, C. L., Gladding, R. L., Frankland, M. P., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.213231 · Cited by 41 · see citing works

Recent trends in treatment strategies for Alzheimer's disease and the challenges: A topical advancement

Liu, N., Liang, X., Chen, Y., & Xie, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102199 · Cited by 41 · see citing works

CA-30, an oligosaccharide fraction derived from Liuwei Dihuang decoction, ameliorates cognitive deterioration via the intestinal microbiome in the senescence-accelerated mouse prone 8 strain

Wang, J., Lei, X., Xie, Z., Zhang, X., Cheng, X., Zhou, W., & Zhang, Y. (2019) · Aging · doi:10.18632/aging.101990 · Cited by 39 · see citing works

O-GlcNAcylation and neuronal energy status: Implications for Alzheimer’s disease

Pinho, T. S., Verde, D. V., Correia, S. C., Cardoso, S., & Moreira, P. I. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.003 · Cited by 38 · see citing works

Brain O-GlcNAcylation: Bridging physiological functions, disease mechanisms, and therapeutic applications

Chen, L., Jiang, H., Licinio, J., & Wu, H. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02943-z · Cited by 33 · see citing works

Glycan Mimetics from Natural Products: New Therapeutic Opportunities for Neurodegenerative Disease

Wang, W., Gopal, S., Pocock, R., & Xiao, Z. (2019) · Molecules · doi:10.3390/molecules24244604 · Cited by 35 · see citing works

Tandem Bioorthogonal Labeling Uncovers Endogenous Cotranslationally O-GlcNAc Modified Nascent Proteins

Zhu, Y., Willems, L. I., Salas, D., Cecioni, S., Wu, W. B., Foster, L. J., & Vocadlo, D. J. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c04121 · Cited by 35 · see citing works

O-GlcNAc cycling in the developing, adult and geriatric brain

Lagerlöf, O. (2018) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-018-9760-1 · Cited by 35 · see citing works

The Role of Insulin Resistance and Protein O-GlcNAcylation in Neurodegeneration

Ansari, S. A., & Emerald, B. S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00473 · Cited by 35 · see citing works

Repeated hypoxia exposure induces cognitive dysfunction, brain inflammation, and amyloidβ/ p -Tau accumulation through reduced brain O -GlcNAcylation in zebrafish

Park, J. W., Jung, S., Kim, S.-M., Park, I. Y., Bui, N. A., Hwang, G., & Han, I. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211027381 · Cited by 34 · see citing works

Discovery and clinical translation of ceperognastat, an O‐GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's disease

Kielbasa, W., Goldsmith, P., Donnelly, K. B., Nuthall, H. N., Shcherbinin, S., Fleisher, A., Hendle, J., DuBois, S. L., Lowe, S. L., Zhang, F. F., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70020 · Cited by 30 · see citing works

New Insights Into the Biology of Protein O-GlcNAcylation: Approaches and Observations

Mueller, T., Ouyang, X., Johnson, M. S., Qian, W., Chatham, J. C., Darley-Usmar, V. M., & Zhang, J. (2021) · Frontiers in Aging · doi:10.3389/fragi.2020.620382 · Cited by 30 · see citing works

Emerging roles of O-GlcNAcylation in protein trafficking and secretion

Zhang, J., & Wang, Y. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.105677 · Cited by 30 · see citing works

Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy

Siwecka, N., Saramowicz, K., Galita, G., Rozpędek‐Kamińska, W., & Majsterek, I. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082051 · Cited by 31 · see citing works

The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome

Zuliani, I., Lanzillotta, C., Tramutola, A., Francioso, A., Pagnotta, S. E., Barone, E., Marzia Perluigi, A., & Domenico, F. D. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00978-4 · Cited by 29 · see citing works

Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings

Duggal, P., & Mehan, S. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190125 · Cited by 28 · see citing works

Therapeutic potential of rescuing protein O-GlcNAcylation in tau-related pathologies

Domenico, F. D., Lanzillotta, C., & Tramutola, A. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1540932 · Cited by 27 · see citing works

Protein glycosylation and glycoinformatics for novel biomarker discovery in neurodegenerative diseases

Costa, J., Hayes, C. A., & Lisacek, F. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101991 · Cited by 26 · see citing works

Defining the Dynamic Regulation of O-GlcNAc Proteome in the Mouse Cortex---the O-GlcNAcylation of Synaptic and Trafficking Proteins Related to Neurodegenerative Diseases

Huynh, N. V., Wang, S., Ouyang, X., Wani, W. Y., Johnson, M. S., Chacko, B. K., Jegga, A. G., Qian, W., Chatham, J. C., Darley-Usmar, V. M., et al. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.757801 · Cited by 24 · see citing works

Hexosamine biosynthetic pathway and O-GlcNAc cycling of glucose metabolism in brain function and disease

Kim, D. Y., Park, J., & Han, I. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00191.2023 · Cited by 24 · see citing works

A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies

Hering, H., Bussière, T., Liu, C., Glajch, K. E., Weihofen, A., Grogan, J. L., & Walsh, D. M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00872-7 · Cited by 26 · see citing works

Tau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma

Hedna, R., Kovacic, H., Pagano, A., Peyrot, V., Robin, M., Devred, F., & Breuzard, G. (2022) · Cancers · doi:10.3390/cancers14215386 · Cited by 24 · see citing works

Potent De Novo Macrocyclic Peptides That Inhibit O‐GlcNAc Transferase through an Allosteric Mechanism

Alteen, M. G., Peacock, H., Meek, R. W., Busmann, J. A., Zhu, S., Davies, G. J., Suga, H., & Vocadlo, D. J. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202215671 · Cited by 23 · see citing works

Chronic rapid eye movement sleep deprivation aggravates the pathogenesis of Alzheimer’s disease by decreasing brain O-GlcNAc cycling in mice

Kim, D. Y., Kim, S.-M., & Han, I. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03179-4 · Cited by 23 · see citing works

Recent Tau-Targeted Clinical Strategies for the Treatment of Alzheimer's Disease

Lee, H. E., Lim, D., Lee, J. Y., Lim, S. M., & Pae, A. N. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0151 · Cited by 23 · see citing works

Regulation of Glycogen Synthase Kinase-3β by Phosphorylation and O-β-Linked N-Acetylglucosaminylation: Implications on Tau Protein Phosphorylation

Hajjar, L. E., Page, A., Bridot, C., Cantrelle, F., Landrieu, I., & Smet‐Nocca, C. (2024) · Biochemistry · doi:10.1021/acs.biochem.4c00095 · Cited by 22 · see citing works

Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders

Martínez‐Viturro, C. M., Trabanco, A. A., Royes, J., Fernández, E., Tresadern, G., Vega, J. A., del Cerro, A., Delgado, F., Molina, A. G., Tovar, F., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01479 · Cited by 23 · see citing works

Increasing O-GlcNAcylation Attenuates tau Hyperphosphorylation and Behavioral Impairment in rTg4510 Tauopathy Mice

Rostgaard, N., Jul, P., Garmer, M., & Volbracht, C. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2205135 · Cited by 21 · see citing works

Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy

Shoeibi, A., Olfati, N., & Litvan, I. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1460356 · Cited by 22 · see citing works

Redox imbalance and metabolic defects in the context of Alzheimer disease

Domenico, F. D., Lanzillotta, C., & Marzia Perluigi, A. (2024) · FEBS Letters · doi:10.1002/1873-3468.14840 · Cited by 22 · see citing works

O-GlcNAc regulates the mitochondrial integrated stress response by regulating ATF4

Alghusen, I. M., Carman, M. S., Wilkins, H., Ephrame, S. J., Qiang, A., Dias, W. B., Fedosyuk, H., Denson, A. R., Swerdlow, R. H., & Slawson, C. M. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1326127 · Cited by 21 · see citing works

Disease-modifying therapies for tauopathies: agents in the pipeline

Panza, F., Imbimbo, B. P., Lozupone, M., Greco, A., Seripa, D., Logroscino, G., Daniele, A., & Colosimo, C. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1606715 · Cited by 19 · see citing works

Emerging disease‐modifying strategies targeting α‐synuclein for the treatment of Parkinson's disease

O’Hara, D. M., Kalia, S. K., & Kalia, L. V. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14345 · Cited by 19 · see citing works

Exogenous IGF-1 improves tau pathology and neuronal pyroptosis in high-fat diet mice with cognitive dysfunction

Sui, G., Yang, C., Wang, L., Xiong, X., Guo, M., Chen, Z., & Wang, F. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00787-4 · Cited by 19 · see citing works

Novel Therapies for Parkinsonian Syndromes–Recent Progress and Future Perspectives

Przewodowska, D., Marzec, W. Z., & Madetko‐Alster, N. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.720220 · Cited by 19 · see citing works

Acute inhibition of OGA sex-dependently alters the networks associated with bioenergetics, autophagy, and neurodegeneration

Huynh, N. V., Benavides, G. A., Johnson, M. S., Ouyang, X., Chacko, B. K., Osuma, E., Mueller, T., Chatham, J. C., Darley-Usmar, V. M., & Zhang, J. (2022) · Molecular Brain · doi:10.1186/s13041-022-00906-x · Cited by 18 · see citing works

The O -GlcNAc cycling in neurodevelopment and associated diseases

Wenzel, D. M., & Stichelen, S. O.-V. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220539 · Cited by 18 · see citing works

In Vivo Validation of a Small Molecule Inhibitor of Tau Self-Association in htau Mice

Davidowitz, E. J., Krishnamurthy, P., Lopez, P. L. D. C., Jimenez, H. T., Adrien, L. R., Davies, P., & Moe, J. G. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190465 · Cited by 17 · see citing works

Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice

Pan, D., Gu, J., Zhang, J., Hu, Y.-E., Liu, F., Iqbal, K., Cekic, N., Vocadlo, D. J., Dai, C., & Gong, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201450 · Cited by 17 · see citing works

Mapping the O-GlcNAc Modified Proteome: Applications for Health and Disease

Burt, R. A., Alghusen, I. M., Ephrame, S. J., Villar, M. T., Artigues, A., & Slawson, C. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.920727 · Cited by 15 · see citing works

The alteration and role of glycoconjugates in Alzheimer’s disease

Kang, Y., Zhang, Q., Xu, S., & Yu, Y. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1398641 · Cited by 15 · see citing works

Recent Advances in Mass Spectrometry-Based Studies of Post-Translational Modifications in Alzheimer’s Disease

Wu, F., Li, W., Lu, H., & Li, L. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101003 · Cited by 16 · see citing works

A Chemical Genetic Method for Monitoring Genome-Wide Dynamics of O-GlcNAc Turnover on Chromatin-Associated Proteins

Liu, T.-W., Myschyshyn, M., Sinclair, D. A. R., & Vocadlo, D. J. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00044 · Cited by 15 · see citing works

Disease-modifying strategies in primary tauopathies

Rösler, T. W., Costa, M., & Höglinger, G. U. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107842 · Cited by 14 · see citing works

FTLD Treatment: Current Practice and Future Possibilities

Ljubenkov, P. A., & Boxer, A. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51140-1_18 · Cited by 13 · see citing works

Development of a PET Tracer for OGA with Improved Kinetics in the Living Brain

Cook, B. E., Nag, S., Arakawa, R., Lin, E. Y.-S., Stratman, N. C., Guckian, K. M., Hering, H., Lulla, M., Choi, J., Salinas, C. A., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265225 · Cited by 13 · see citing works

Molecular Insights into Tau Pathology and its Therapeutic Strategies in Alzheimer's Disease

Zhou, F., Zhao, Y., Sun, Y., & Chen, W. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2311197 · Cited by 13 · see citing works

Progress in the treatment of Parkinson-Plus syndromes

Olfati, N., Shoeibi, A., & Litvan, I. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.10.006 · Cited by 12 · see citing works

Deciphering the Structure and Formation of Amyloids in Neurodegenerative Diseases With Chemical Biology Tools

Landrieu, I., Dupré, E., Sinnaeve, D., Hajjar, L. E., & Smet‐Nocca, C. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.886382 · Cited by 11 · see citing works

Tau Diagnostics and Clinical Studies

Gozes, I., Höglinger, G. U., Quinn, J. P., Hooper, N. M., & Höglund, K. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0983-0 · Cited by 12 · see citing works

O-GlcNAc modification differentially regulates microtubule binding and pathological conformations of tau isoforms in vitro

Alhadidy, M. M., Stemmer, P. M., & Kanaan, N. M. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108263 · Cited by 11 · see citing works

Diaminocyclopentane-derived O -GlcNAcase inhibitors for combating tau hyperphosphorylation in Alzheimer's disease

Weber, P., Mészáros, Z., Jagečić, D., Hribljan, V., Mitrečić, D., Bojarová, P., Slámová, K., Vrba, J., Kulik, N., Vladimír Křen, A., et al. (2022) · Chemical Communications · doi:10.1039/d2cc02712g · Cited by 11 · see citing works

Enhancing protein O-GlcNAcylation in down syndrome mice mitigates memory dysfunctions through the rescue of mitochondrial bioenergetics, stress responses and pathological markers

Lanzillotta, C., Prestia, F., Greco, V., Iavarone, F., Cordella, F., Sette, C., Forte, E., Tramutola, A., Lanzillotta, S., Cassano, T., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103769 · Cited by 10 · see citing works

Pathophysiological interplay between O -GlcNAc transferase and the Machado–Joseph disease protein ataxin-3

Sena, P. P., Weber, J. J., Watchon, M., Robinson, K. J., Wassouf, Z., Hauser, S., Helm, J., Abeditashi, M., Schmidt, J., Hübener‐Schmid, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025810118 · Cited by 10 · see citing works

Twenty years of therapeutic development in tauopathy mouse models: a scoping review

Langness, V. F., Simmons, D. A., McHugh, T. L. M., Butler, R. R., Zhou, J., Liu, H., Yang, T., Ellerby, L., & Longo, F. M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70578 · Cited by 9 · see citing works

Current trends and updates in the treatment of Alzheimer's disease

Parikh, N. H., Parikh, P. K., Rao, H. J., Shah, K., Dave, B. P., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00014-5 · Cited by 9 · see citing works

Synaptic toxicity of OGA inhibitors and the failure of ceperognastat

Meade, J., Mesa, H., Alamgir, S., Bieniecka, I., Liu, L., & Zhang, Q. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100456 · Cited by 8 · see citing works

Increasing O-GlcNAcylation Attenuates tau Hyperphosphorylation and Behavioral Impairment in rTg4510 Tauopathy Mice

Rostgaard, N., Jul, P., Garmer, M., & Volbracht, C. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2205135 · Cited by 21 · see citing works

MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy

Wang, X., Li, W., Marcus, J., Pearson, M. S., Song, L., Smith, K. D. B., Terracina, G., Lee, J. A., Hong, K.-L. K., Lu, S. X., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.266122 · Cited by 83 · see citing works

P4‐367: CHRONIC O‐B‐N‐ACETYLGLUCOSAMINYLASE INHIBITION WITH THIAMET‐G PREVENTS TAU PATHOLOGY AND HYPERACTIVITY IN RTG4510 MICE

Volbracht, C., Rostgaard, N., & Jul, P. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.07.137 · Cited by 1 · see citing works

Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy

Graham, D. L., Gray, A. J., Joyce, J. A., Yu, D., O’Moore, J., Carlson, G. A., Shearman, M. S., Dellovade, T., & Hering, H. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.025 · Cited by 129 · see citing works

Development of functional tools to study the role of O-GlcNAc in tau biology

Yuzwa, S. A. (2013) · Summit (Simon Fraser University)